ClinicalTrials.gg
RecruitingNCT06942572ASTRAUpdated Apr 29, 2025

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

A Phase 1/2 interventional study of SB-007 in Stargardt Disease, Stargardt Macular Degeneration and Stargardt Macular Dystrophy, sponsored by Splice Bio. Recruiting at 5 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Splice Bio · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
11th of 26
57 · median 41
Started
2025
with 3 others
Phase 1/2
7 of 42
3 open now
Primary completion
2028-10
later than 12 of 24 live
Registered
35th of 42
by date

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 11th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 12 of the 24 other live ones, and was the 35th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1).

This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.

Read the detailed description

Inherited retinal dystrophies (IRDs) are a group of genetically and clinically heterogeneous disorders caused by progressive degeneration of photoreceptor (PR) rods, cones, or both. The majority of IRDs are characterized by retinal degeneration, which can lead to significant vision impairment and blindness and are thus serious and debilitating conditions. Most IRDs have no treatment options.

Stargardt disease (STGD1) is an autosomal recessive IRD that generally manifests during childhood or early adulthood. It has an estimated prevalence of 1 in 8,000 to 10,000 patients. STGD1 is due to mutations in the adenosine triphosphate (ATP)-binding cassette, sub-family A, member 4 (ABCA4) gene. The ABCA4 protein is an ATP-binding cassette (ABC) transporter expressed in PR outer segments in both rods and cones. This protein plays a critical role in the visual phototransduction cycle. Mutations in the ABCA4 gene adversely affect the metabolism of vitamin A, leading to deposition and build-up of lipofuscin containing bisretinoid toxins, such as N-retinylidene-N-retinylethanolamine (A2E), in the PRs and retinal pigment epithelium (RPE) cells. This accumulation of lipofuscin causes the formation of yellowish flecks over the macula and toxins such as A2E lead to oxidative stress and death of RPE cells and light-sensing photoreceptors.

Gene therapies are emerging as potentially viable treatments for a variety of IRDs. Many of these therapies are based on the use of adeno-associated virus (AAV) vectors containing DNA that encodes a functional gene to replace a defective gene.

Although AAV vectors have good biological characteristics (i.e., high transduction efficiency, genetic stability) and acceptable safety profiles (non-immunogenic, non-pathogenic, few serious adverse effects), one drawback is its packaging capability. Until recently, use of AAV vectors was not considered appropriate for STGD1 gene therapies since the ABCA4 gene is too large and exceeds the capacity of AAV vectors. However, SpliceBio, a genetic medicines company, has developed a proprietary protein splicing intein platform using dual AAV vectors that enables the delivery of genes too large for conventional AAV vector systems. SpliceBio is using this technology to develop a genetic treatment for STGD1.

SB-007 is a new gene therapy investigational medicinal product based on dual AAV8 gene delivery for the full-length reconstitution of the ABCA4 protein inside the target cell using protein trans-splicing mediated by small polypeptidic proprietary sequences called split-inteins. While each alone are inactive, the co-expression of the 2 vectors is expected to lead to highly efficient PTS and reconstitution of the full-length biologically active ABCA4 protein in target photoreceptor cells. Further, SB-007 is anticipated to enable long-term expression of a functional wild type ABCA4 protein in the retina of patients and thus slow or blunt further vision loss after a single subretinal administration.

First-in-human trials are conducted primarily to determine the safe dose range for further clinical development of promising drug candidates. This first-in-human study is being conducted to identify doses of SB-007 that are safe and demonstrate a potential efficacy signal in subjects with moderate or advanced STGD1.

03

Conditions studied

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy

Browse trials for

Keywords

  • Gene Therapy
  • SB-007
  • Splicebio
  • Stargardt
  • Stargardts Disease
  • SGDT1
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for study participation, subjects must meet the following criteria:

  1. Provide written consent. Subjects under legal age will also provide informed assent according to guidelines set forth by the same.
  2. Are male or female adolescents and adults, aged as follows:

    1. In Part A, subjects will be ≥18 to ≤65* years (inclusive)
    2. In Part B, subject age is planned as ≥12 to ≤65* years (inclusive) *Subjects aged >65 years may be eligible in Parts A and B, following discussion with, and approval by, the Medical Monitor.
  3. Are able to understand and comply with the study procedures.
  4. Have a diagnosis of STGD1 caused by bi-allelic pathogenic, or likely pathogenic, variants in the ABCA4 gene confirmed genotypically by an accredited genetic testing laboratory
  5. Clinical evidence consistent with Stargardt Disease type 1.
  6. For women of (WOCBP), have a negative pregnancy test at Screening and, if due to receive active treatment, at Day 0.
  7. For both WOCBP and male subjects (or their female partners who are of child-bearing potential), agree to either strict abstinence or, if sexually active, use an acceptable measure for 3 months from Day 0
  8. Must have clear ocular media and adequate pupillary dilation in the study eye, including no allergy to dilating eyedrops, to permit good quality retinal imaging.
  9. Fulfil visual acuity criteria based on ETDRS letter chart
  10. Fulfil baseline lesion size measurement, as measured by the Reading Center
  11. Evidence of disease progression as determined by the Medical Monitor following consultation with the Investigator.

Exclusion criteria

Exclusion Criteria:

Subjects must be excluded from participating in the study if they:

  1. Have had any intraocular surgery (including cataract surgery) or thermal laser within 90 days of the Screening Visit or planned intraocular surgery (including cataract surgery) or thermal laser during the period of the study, in the study eye.
  2. Have had any major surgical procedure within 30 days of the Screening Visit or planned or anticipated major surgery during the period of the study.
  3. Have two pathogenic or likely pathogenic variants in IRD genes (other than ABCA4) or a single pathogenic or likely pathogenic variant in autosomal dominant or X-linked IRD genes.
  4. Have a history of amblyopia in the study eye.
  5. Are unwilling to stop taking the following products at Screening and throughout the study:

    1. Supplements containing vitamin A or beta-carotene, liver-based products.
    2. Prescription oral retinoids. Topical products containing vitamin A or retinoids are not exclusionary.
  6. Have any ophthalmic history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or intravitreal or sub-retinal or supra-choroidal injections.
  7. Have received any therapy within 90 days of the Screening Visit or 5 half-lives, whichever is longer.
  8. Have known serious allergies to the fluorescein dye that might be used to measure IOP, ocular dilating drops, topical ocular anesthetic, medication, or components of the SB-007 formulation.
  9. Have any significant ocular or non-ocular disease/disorder which, in the opinion of the Investigator and with concurrence of the Medical Monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or affect the subject's ability to participate in the study.
  10. Are an immediate family member (e.g., child, sibling) of the Sponsor or study site personnel.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation - Low Dose

    Low Dose: Subjects will receive subretinal injection of SB-007 in the low dose group

    Genetic: SB-007

  • Experimental
    Phase 1 Dose Escalation - Medium Dose

    Medium Dose: Subjects will receive subretinal injection of SB-007 in the medium dose group

    Genetic: SB-007

  • Experimental
    Phase 1 Dose Escalation - High Dose

    High Dose: Subjects will receive subretinal injection of SB-007 in the high dose group

    Genetic: SB-007

  • Experimental
    Phase 2 Dose Expansion: Dose 1 from Phase 1 Randomised Arm

    Subjects will receive a subretinal injection of SB-007 with Maximum tolerated dose (MTD) from Phase 1

    Genetic: SB-007

  • Experimental
    Phase 2 Dose Expansion: Dose 2 from Phase 1 Randomised Arm

    Subjects will receive a subretinal injection of SB-007 with lower dose than Maximum tolerated dose (MTD) from Phase 1

    Genetic: SB-007

  • No intervention
    Phase 2 No Intervention - Randomised Control Arm

    No Intervention Control Arm: Subject will not receive any active study intervention

Interventions

  • GeneticSB-007

    Subretinal Administration of SB-007

06

What researchers measure

Primary outcomes

  1. Safety Measures

    Safety and tolerability assessed by incidence and/or clinically significant changes in ocular and non-ocular AEs

    Time frame: 96 weeks

Secondary outcomes

  1. Efficacy Measure: Change from baseline in lesion size using autofluorescence (FAF)

    Change from baseline in lesion size growth (mm\^2) on FAF imaging compared between SB-007 and untreated control at Week 96, adjudicated by a Central Reading Center

    Time frame: 96 weeks (Screening to 96 weeks post SB-007 administration)

  2. Other Efficacy Measure: Change from baseline in retinal sensitivity

    Change from baseline in retinal sensitivity based on microperimetry at Weeks 48 and 96

    Time frame: 48 and 96 weeks (Screening to 48 and 96 weeks post SB-007 administration)

  3. Other Efficacy Measure: Change from baseline in BCVA (Best Corrected Visual Acuity)

    Change from baseline in BCVA using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score at Weeks 48 and 96

    Time frame: 48 and 96 weeks (Screening to 48 and 96 weeks post SB-007 administration)

  4. Other Efficacy Measure: Change from baseline in LLVA (Low Luminance Visual Acuity)

    Change from baseline in LLVA using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Weeks 48 and 96. A higher score represents better vision at low light levels.

    Time frame: 48 and 96 weeks (Screening to 48 and 96 weeks post SB-007 administration)

  5. Other Efficacy Measure: Change in Quality of Life measure using MRDQ

    The Michigan Retinal Dystrophy Questionnaire (MRDQ) is a patient reported outcome measure that will be administered to assess visual function in subjects with Inherited Retinal Dystrophies

    Time frame: 48 and 96 weeks (Screening to 48 and 96 weeks post SB-007 administration)

  6. Other Efficacy Measure: Change in Quality of Life measure using PGI questionnaires

    These Patient Global Impression (PGI) scales evaluate all aspects of a patients health and assesses if there has been an improvement or decline in clinical status

    Time frame: 48 and 96 weeks (Screening to 48 and 96 weeks post SB-007 administration)

07

Study locations

5 of 5 sites recruiting
  • UCHealth Sue Anschutz-Rodgers Eye Center,
    Aurora, Colorado 80045, United States
    Recruiting
    • Site 109 · Principal investigator
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
    Recruiting
    • Site 104 · Principal investigator
  • Massachusetts Eye and Ear Infirmary
    Boston, Massachusetts 02114, United States
    Recruiting
    • Center for Clinical Research · Contact
    • Site 105 · Principal investigator
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Site 103 · Principal investigator
  • Retina Foundation of the Southwest
    Dallas, Texas 75261, United States
    Recruiting
    • Site 102 · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Oct 2028, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Apr 24, 2025
StartActual
Feb 11, 2025
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942572
Lead sponsor
Splice Bio
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Feb 11, 2025
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 29, 2025

Study contacts

SpliceBio
Contact
clinicaltrials@splice.bio
+34 934 02 04 56

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion